EP4705556A2 - Génération et classement de fragments d'anticorps fab à haut débit - Google Patents

Génération et classement de fragments d'anticorps fab à haut débit

Info

Publication number
EP4705556A2
EP4705556A2 EP24800595.1A EP24800595A EP4705556A2 EP 4705556 A2 EP4705556 A2 EP 4705556A2 EP 24800595 A EP24800595 A EP 24800595A EP 4705556 A2 EP4705556 A2 EP 4705556A2
Authority
EP
European Patent Office
Prior art keywords
antibody
pool
antibodies
antibody fragments
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24800595.1A
Other languages
German (de)
English (en)
Inventor
Daria SIZOVA
Yazen JMEIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of EP4705556A2 publication Critical patent/EP4705556A2/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes et des dosages destinés au classement à haut débit de liaison à l'antigène par génération et test de fragments d'anticorps à partir d'anticorps pleine longueur.
EP24800595.1A 2023-05-04 2024-05-02 Génération et classement de fragments d'anticorps fab à haut débit Pending EP4705556A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363463995P 2023-05-04 2023-05-04
PCT/US2024/027448 WO2024229245A2 (fr) 2023-05-04 2024-05-02 Génération et classement de fragments d'anticorps fab à haut débit

Publications (1)

Publication Number Publication Date
EP4705556A2 true EP4705556A2 (fr) 2026-03-11

Family

ID=93333493

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24800595.1A Pending EP4705556A2 (fr) 2023-05-04 2024-05-02 Génération et classement de fragments d'anticorps fab à haut débit

Country Status (3)

Country Link
EP (1) EP4705556A2 (fr)
CN (1) CN121285662A (fr)
WO (1) WO2024229245A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069731A1 (fr) * 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonistes d'anticorps dirigés contre un peptide associé au gène de la calcitonine et procédés les utilisant

Also Published As

Publication number Publication date
WO2024229245A9 (fr) 2024-12-26
CN121285662A (zh) 2026-01-06
WO2024229245A3 (fr) 2025-02-06
WO2024229245A2 (fr) 2024-11-07

Similar Documents

Publication Publication Date Title
EP2871189A1 (fr) Anticorps TAG anti Strep monoclonaux à affinité élevée
US10604586B2 (en) Humanized monoclonal antibody and uses thereof
CN108026180B (zh) 抗羟腐胺赖氨酸抗体及其用途
EP3650547A1 (fr) Anticorps monoclonal anti-igg4 humaine et réactif de dosage d'igg4 humaine l'utilisant
JP2025503573A (ja) 抗ｇｐｒｃ５ｄ抗体及びその応用
EP3533459A1 (fr) Anticorps anti-pla2-gib et leurs utilisations
CN116925230A (zh) 一种抗人pla2r的抗体及其抗原结合片段及其应用
US8753632B2 (en) Antibodies to modified human IGF-1/E peptides
CN113544157B (zh) 用于检测或捕获样品中的多肽的抗体和组合物，以及用于检测或捕获样品中的多肽的方法
CN109336973B (zh) 抗转铁蛋白抗体及其用途
EP4705556A2 (fr) Génération et classement de fragments d'anticorps fab à haut débit
CN120225680A (zh) 针对外被体蛋白复合物亚基β2的抗体
EP4441100A1 (fr) Anticorps à domaine unique bloquant et non bloquants et leurs utilisations
WO2022078466A1 (fr) Procédés d'atténuation de l'interférence par des anticorps anti-cd47 thérapeutiques dans des dosages de pré-transfusion
CN119735680B (zh) 一种抗cd28的单克隆抗体及细胞
CN110579610A (zh) 用于检测t细胞活化的v域免疫抑制因子的试剂盒
CN119874904B (zh) 抗NT-proBNP抗体及其用途
EP4549462A1 (fr) Anticorps spécifique de propeptide n-terminal de procollagène, kit et utilisation associée
JP7839108B2 (ja) 筋萎縮性側索硬化症の治療用医薬組成物
CN119874896B (zh) 抗cTnI抗体及其用途
RU2859564C2 (ru) Антитела кролика к иммуноглобулинам g человека
WO2025061149A1 (fr) Anticorps anti-gcc, récepteur antigénique chimérique et utilisation
WO2025249551A1 (fr) Méthode permettant de quantifier le mésappariement de l'échange de chaînes légères d'un anticorps bispécifique
JP7107497B2 (ja) Ｄｎａ鎖上のアデノシン型サイクロプリンに特異的に結合する抗体
JP2023513282A (ja) 抗ｃｄ１９キメラ抗原受容体を標的とする抗イディオタイプ抗体

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR